Spots Global Cancer Trial Database for Trial of BMS-986012 in Combination With Platinum and Etoposide
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of BMS-986012 in Combination With Platinum and Etoposide
Official Title: A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
Study ID: NCT02815592
Conditions
Study Description
Brief Summary: The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0002, Barcelona, , Spain
Local Institution - 0004, Madrid, , Spain
Local Institution - 0003, Majadahonda - Madrid, , Spain
Local Institution - 0010, Malaga, , Spain
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
